LeslieSKeanMD
Pediatric Hematology & Oncology • Boston, MAAssociate Professor, Pediatrics, U of WA Sch of Med
Are you Dr. Kean?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 45 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-355-6000
Summary
- Dr. Leslie Kean, MD is a pediatric hematologist/oncologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts, Washington, and Georgia. She is affiliated with Boston Children's Hospital and Dana-Farber Cancer Institute.
Education & Training
Emory University School of MedicineFellowship, Pediatric Hematology/Oncology, 2003 - 2005- Emory University School of MedicineResidency, Pediatrics, 1999 - 2003
- Emory University School of MedicineClass of 1999
Certifications & Licensure
MA State Medical License 2018 - 2025
WA State Medical License 2013 - 2020
GA State Medical License 2003 - 2019- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Start of enrollment: 2009 Nov 01
- Abatacept as GVHD Prophylaxis Phase 2 Start of enrollment: 2013 Feb 01
- Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial) Start of enrollment: 2017 May 01
Publications & Presentations
PubMed
- 107 citationsPhase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.Benjamin Watkins, Muna Qayed, Courtney McCracken, Brandi Bratrude, Kayla Betz
Journal of Clinical Oncology. 2021-01-15 - 56 citationsPersistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant.Maud Mavigner, Benjamin Watkins, Benton Lawson, S. Thera Lee, Ann Chahroudi
Plos Pathogens. 2014-09-25 - 77 citationsStandardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transpla...Mohamed A. Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, Mahmoud Aljurf, Taiga Nishihori
Transplantation and Cellular Therapy. 2021-08-01
Press Mentions
- Pilot Study Investigates Axicabtagene Ciloleucel in Primary and Secondary CNS LymphomaDecember 13th, 2022
- Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Graft-Versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in AnimalsDecember 5th, 2022
- From Our Labs and Clinics: 10 Research Advances in 2021December 30th, 2021
- Join now to see all
Grant Support
- Novel Biologic Therapies For BMT: Mechanistic Evaluation In Rhesus MacaquesNational Heart, Lung, And Blood Institute2010–2012
- Adoptive Cellular Therapies To Enhance Tolerance And Protective ImmunityNational Institute Of Allergy And Infectious Diseases2008–2011
- Innate Immunity And Transplantatation ToleranceNational Institute Of Allergy And Infectious Diseases2006–2009
- Innate Immunity And Transplantation ToleranceNational Institute Of Allergy And Infectious Diseases2007
